OSR Holdings, Inc. (NASDAQ:OSRH) Short Interest Update

OSR Holdings, Inc. (NASDAQ:OSRH) was the recipient of a large growth in short interest in April. As of April 30th, there was short interest totaling 1,282,018 shares, a growth of 461.9% from the April 15th total of 228,151 shares. Currently, 9.8% of the company’s shares are sold short. Based on an average daily trading volume, of 28,596,577 shares, the short-interest ratio is presently 0.0 days.

OSR Stock Down 2.7%

Shares of NASDAQ:OSRH opened at $0.60 on Friday. OSR has a twelve month low of $0.38 and a twelve month high of $1.79. The stock’s 50 day moving average is $0.54 and its 200-day moving average is $0.58. The firm has a market capitalization of $21.06 million, a price-to-earnings ratio of -1.82 and a beta of 0.86.

OSR (NASDAQ:OSRH) last issued its earnings results on Wednesday, May 13th. The company reported ($0.09) earnings per share for the quarter. OSR had a negative return on equity of 7.16% and a negative net margin of 363.26%.The firm had revenue of $0.48 million for the quarter.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on OSRH. Weiss Ratings restated a “sell (e+)” rating on shares of OSR in a report on Friday, March 27th. Wall Street Zen upgraded OSR from a “strong sell” rating to a “sell” rating in a report on Saturday, April 25th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has an average rating of “Sell”.

Hedge Funds Weigh In On OSR

An institutional investor recently bought a new position in OSR stock. Susquehanna International Group LLP bought a new position in shares of OSR Holdings, Inc. (NASDAQ:OSRH) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 79,807 shares of the company’s stock, valued at approximately $43,000. Susquehanna International Group LLP owned 0.37% of OSR as of its most recent SEC filing. 55.30% of the stock is currently owned by hedge funds and other institutional investors.

OSR Company Profile

OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials.